MacDougall Biomedical Clients in San Francisco
January 13-16, 2014

- IR Meeting Requests -

MBI will be hosting 1x1 meetings for the companies listed below January 13-16, 2014, in San Francisco, CA. These meetings will take place in our suites at the Parc 55 Wyndham, unless otherwise noted. If you are interested in meeting one or more of our clients, please complete the registration form below or e-mail us at MBISF@macbiocom.com.

 

The Parc 55 Wyndham is located  at 55 Cyril Magnin St in Union Square, a 5 minute walk from the Westin St. Francis.

 

Contact Information
* Required


Monday, January 13, 2014

Breakfast Meeting
8:00AM-10:00AM (PT)
10:00AM-12:00PM (PT)
12:00PM-2:00PM (PT)
2:00PM - 5:00PM (PT)
Dinner Meeting

Tuesday, January 14, 2014
Breakfast Meeting
8:00AM-10:00AM (PT)
10:00AM-12:00PM (PT)
12:00PM-2:00PM (PT)
2:00PM - 5:00PM (PT)
Dinner Meeting

Wednesday, January 15, 2014
Breakfast Meeting
8:00AM-10:00AM (PT)
10:00AM-12:00PM (PT)
12:00PM-2:00PM (PT)
2:00PM - 5:00PM (PT)
Dinner Meeting

Thursday, January 16, 2014
Breakfast Meeting
8:00AM-10:00AM (PT)
10:00AM-12:00PM (PT)
12:00PM-2:00PM (PT)
2:00PM - 5:00PM (PT)
Dinner Meeting

Monday, January 13, 6:00 AM (PT) – 4 mile fun run to kick off the week – meet in Union Square directly across from the Westin St. Francis (at the Dewey Monument)

Bavarian Nordic (CPH: BAVA) is developing off-the-shelf cancer immunotherapies, including PROSTVAC® (Phase 3 in mCRPC) and CV-301 (Phase 2). In 2013, the company’s successful biodefense business secured a new $228M U.S. government supply contract for its smallpox vaccine IMVAMUNE® (now approved in the EU as IMVANEX®).

Five Prime Therapeutics' (NASDAQ: FPRX) unique protein discovery platform has identified a library of over 5,600 human extracellular proteins, which may represent substantially all medically important targets for protein therapeutics. The Company has generated more than $220M from collaborations to date, has active R&D partnerships with GSK and UCB, and is advancing three candidates focused on cancer and inflammatory diseases. Lead compound, FP-1039, targeting FPFR1 has potential to be best in class and is in Phase 1b for squamous NSCLC and other tumors. A second clinical candidate, FPA008, is being developed for RA. Data for each is expected in 2014.

MacroGenics (NASDAQ: MGNX) has generated a pipeline of optimized antibodies, including Margetuximab which is currently in Phase 2 for relapsed and refractory breast cancer patients with low HER2 expression, and a portfolio of partnerships all based on their proprietary platform of three antibody technologies including: Fc optimization, the DART bispecific engineering and cancer stem cell targeting.

Onconova Therapeutics (NASDAQ: ONTX) is developing rigosertib, a dual PI3K/PLK inhibitor, in both IV and oral formulations. Phase 2 data in lower risk MDS will be announced at ASH, Phase 3 data in higher risk MDS are expected in 4Q13/1Q14, and Phase 3 interim results in pancreatic cancer are expected 4Q13/1Q14. Onconova has a $500m+ EU partnership with Baxter 2012 and retains US commercial rights.

Skyepharma plc (LSE:SKP) utilizes its proprietary drug delivery technologies to develop complex inhalation and oral products for a variety of indications. The company has multiple pharma partnerships and receives royalties on 14 marketed products, with six major product approvals (including Flutiform, BREO ELLIPTA/RELVAR ELLIPTA, Requip once-a-day and Paxil CR, Rayos) in key markets over the past 18 months. Revenues in the first half of 2013 were up 58% at ~US$51 million.

Summit Corporation plc (AIM: SUMM) is developing a utrophin modulator in DMD, a candidate with disease-modifying potential for all boys with DMD. A Phase 1b trial in patients is expected to begin shortly, followed by a Phase 2 in 2H14. In addition, Summit has a novel C. diff antibiotic entering Phase 2 in 1H14.

Acetylon Pharmaceuticals signed a deal with Celgene in 2013 for Acetylon’s selective HDAC candidates, which included $100M upfront, up to $1.1B in future milestones and the option for Celgene to acquire Acetylon. Lead candidate ACY-1215 (HDAC6 inhibitor) is in two clinical trials for multiple myeloma and has demonstrated early signs of efficacy. Data and additional clinical trials are expected in 2014.

Aerpio is developing innovative therapies for vascular diseases by targeting the Tie2 pathway. Its lead candidate, AKB-9778, has completed a successful Phase 1a/2b study in diabetic macular edema (DME), demonstrating early signs of efficacy. AKB-9778 is unique in the DME space in both its MOA (which activates Tie2 independently of VEG-F) and its route of administration (self-administered), and could be used as a monotherapy or in combination with currently marketed therapies. The Company plans to initiate a larger confirmatory Phase 2 study in 2014.

Cerecor is developing an NR2B antagonist as a rapid-acting antidepressant. The candidate, CERC-301, has demonstrated rapid antidepressant effects in a pilot study conducted by the NIMH, and is currently in a Phase 2 study with results expected 2H14. In addition, the Company has a COMT inhibitor platform for the treatment of cognitive disorders for numerous CNS disorders.

ImaginAb, Inc. uses its antibody engineering technology to develop in vivo imaging agents that improve upon Positron Emission Tomography (PET) diagnoses in oncology. The company also applies its technology to novel therapeutics in oncology and is now expanding the reach and resolution of its imaging into first-in-class immunology capabilities. ImaginAb has a deep portfolio proprietary clinical-stage and research candidates and partnered programs with companies such as Astellas, Lundbeck, and Macrogenics.

Isarna is in the cancer immunotherapy space, developing oligonucleotides to inhibit TGF-beta, a target in which the company has enormous expertise. In the near term, the company is rapidly advancing 2 compounds into the clinic, key validating events for the company’s approach.

T2 Biosystems has a flagship sepsis diagnostic product, T2Candida, currently in a pivotal clinical trial with results expected 1H14. T2Candida detects species-specific Candida directly from whole blood in approximately three hours, compared to the gold standard of blood culture, which takes two to five days. By rapidly detecting Candida, T2Candida could provide significant life- and cost-savings.


You will receive an email confirmation of your request.